Hallmarks of response, resistance, and toxicity to immune checkpoint blockade
G Morad, BA Helmink, P Sharma, JA Wargo - Cell, 2021 - cell.com
Unprecedented advances have been made in cancer treatment with the use of immune
checkpoint blockade (ICB). However, responses are limited to a subset of patients, and …
checkpoint blockade (ICB). However, responses are limited to a subset of patients, and …
Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends
Q Sun, Z Hong, C Zhang, L Wang, Z Han… - Signal transduction and …, 2023 - nature.com
Abstract Immune-checkpoint inhibitors (ICBs), in addition to targeting CTLA-4, PD-1, and PD-
L1, novel targeting LAG-3 drugs have also been approved in clinical application. With the …
L1, novel targeting LAG-3 drugs have also been approved in clinical application. With the …
Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update
PURPOSE To increase awareness, outline strategies, and offer guidance on the
recommended management of immune-related adverse events (irAEs) in patients treated …
recommended management of immune-related adverse events (irAEs) in patients treated …
T cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanoma
Severe immune-related adverse events (irAEs) occur in up to 60% of patients with
melanoma treated with immune checkpoint inhibitors (ICIs). However, it is unknown whether …
melanoma treated with immune checkpoint inhibitors (ICIs). However, it is unknown whether …
T follicular helper cells in cancer
T follicular helper (Tfh) cells provide essential help to B cells for effective antibody-mediated
immune responses. Although the crucial function of these CD4+ T cells in infection and …
immune responses. Although the crucial function of these CD4+ T cells in infection and …
Immunotherapy for hepatocellular carcinoma: current status and future prospects
Z Liu, X Liu, J Liang, Y Liu, X Hou, M Zhang… - Frontiers in …, 2021 - frontiersin.org
Hepatocellular carcinoma (HCC) is the most prevalent primary liver cancer with poor
prognosis. Surgery, chemotherapy, and radiofrequency ablation are three conventional …
prognosis. Surgery, chemotherapy, and radiofrequency ablation are three conventional …
PD-1 directed immunotherapy alters Tfh and humoral immune responses to seasonal influenza vaccine
Abstract Anti-programmed death-1 (anti-PD-1) immunotherapy reinvigorates CD8 T cell
responses in patients with cancer but PD-1 is also expressed by other immune cells …
responses in patients with cancer but PD-1 is also expressed by other immune cells …
Targeting Treg cells with GITR activation alleviates resistance to immunotherapy in murine glioblastomas
Immune checkpoint blockers (ICBs) have failed in all phase III glioblastoma (GBM) trials.
Here, we show that regulatory T (Treg) cells play a key role in GBM resistance to ICBs in …
Here, we show that regulatory T (Treg) cells play a key role in GBM resistance to ICBs in …
Immune-checkpoint inhibitor use in patients with cancer and pre-existing autoimmune diseases
Immune-checkpoint inhibitors (ICIs) have dramatically changed the management of
advanced cancers. Designed to enhance the antitumour immune response, they can also …
advanced cancers. Designed to enhance the antitumour immune response, they can also …
Harnessing big data to characterize immune-related adverse events
Immune-checkpoint inhibitors (ICIs) have transformed patient care in oncology but are
associated with a unique spectrum of organ-specific inflammatory toxicities known as …
associated with a unique spectrum of organ-specific inflammatory toxicities known as …